| Parkinson Disease
Ongentys vs Onapgo
Side-by-side clinical, coverage, and cost comparison for parkinson disease.Deep comparison between: Ongentys vs Onapgo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOnapgo has a higher rate of injection site reactions vs Ongentys based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Onapgo but not Ongentys, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ongentys
Onapgo
At A Glance
Oral
Daily
COMT inhibitor
SC injection
Daily continuous infusion
Non-ergoline dopamine agonist
Indications
- Parkinson Disease
- Parkinson Disease
Dosing
Parkinson Disease 50 mg orally once daily at bedtime; avoid food 1 hour before and at least 1 hour after dose; reduce to 25 mg in moderate hepatic impairment (Child-Pugh B); avoid use in severe hepatic impairment (Child-Pugh C).
Parkinson Disease Initial continuous dosage 1 mg/hr SC infusion over the waking day (up to 16 hours), titrated in 0.5-1 mg/hr increments up to 6 mg/hr; extra doses of 0.5-2 mg up to 3 times/day as needed; maximum total daily dosage 98 mg.
Contraindications
- Concomitant use of non-selective monoamine oxidase (MAO) inhibitors
- Pheochromocytoma, paraganglioma, or other catecholamine secreting neoplasms
- Concomitant use of 5HT3 antagonists, including antiemetics (e.g., ondansetron, granisetron, dolasetron, palonosetron) and alosetron
- Hypersensitivity or allergic reaction to apomorphine or any excipient of ONAPGO, including sulfite (sodium metabisulfite)
Adverse Reactions
Most common (>=4%) Dyskinesia, constipation, blood creatine kinase increased, hypotension/syncope, weight decreased
Serious Cardiovascular effects with COMT-metabolized drugs, falling asleep during activities of daily living, hypotension/syncope, dyskinesia, hallucinations and psychosis, impulse control/compulsive disorders, withdrawal-emergent hyperpyrexia and confusion
Postmarketing Fall
Most common (>=10%) Infusion site nodule, nausea, somnolence, infusion site erythema, dyskinesia, headache, insomnia
Serious Syncope, hypotension, orthostatic hypotension, falls, hallucinations, psychotic-like behavior, hemolytic anemia, impulse control disorders, cardiac events, QTc prolongation, hypersensitivity, fibrotic complications, priapism
Postmarketing Hemolytic anemia
Pharmacology
Opicapone is a peripheral, selective and reversible inhibitor of catechol-O-methyltransferase (COMT) that reduces levodopa breakdown to 3-OMD, thereby increasing levodopa exposure in Parkinson's disease patients treated with levodopa/carbidopa.
Non-ergoline dopamine agonist with high binding affinity for the dopamine D4 receptor and moderate affinity for D2, D3, D5, and adrenergic receptors; believed to act via stimulation of post-synaptic dopamine D2-type receptors within the caudate-putamen in the brain.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ongentys
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
Onapgo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Ongentys
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (2/8) · Qty limit (1/8)
Onapgo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Ongentys
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Onapgo
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Ongentys.
No savings programs available for Onapgo.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
OngentysView full Ongentys profile
OnapgoView full Onapgo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.